Physician profile
Michael Frazier
NPI 1225396591
$7,718.28
in general payments reported to CMS, 2019-2025
25 companies · $5,506 in 2025
The $5,506 reported for 2025 was more than what 91% of Behavioral Neurology & Neuropsychiatry providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2020: $137 · 2021: $19.08 · 2023: $16.52 · 2024: $1,875 · 2025: $5,506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,349 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,349.00 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,257.52 | 2024-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $877.57 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $855.20 | 2019-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $816.86 | 2019-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $726.22 | 2024-2025 | Cobenfy |
| Abbvie INC. | $583.68 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $417.62 | 2024-2025 | Invega Sustenna, Spravato |
| Lundbeck LLC | $370.05 | 2024-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $332.55 | 2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $259.21 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Indivior INC. | $229.80 | 2024-2025 | Sublocade, Perseris |
| Axsome Therapeutics, INC. | $214.78 | 2024-2025 | Auvelity |
| Almatica Pharma LLC | $146.16 | 2024-2025 | Loreev Xr |
| Sage Therapeutics, LLC | $111.59 | 2020 | |
| Corium, LLC | $108.84 | 2024-2025 | Azstarys |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $97.27 | 2025 | Aplenzin |
| Collegium Pharmaceutical, INC. | $63.76 | 2025 | Jornay Pm |
| Acadia Pharmaceuticals INC | $60.37 | 2019-2023 | Nuplazid |
| Janssen Scientific Affairs, LLC | $38.80 | 2024 | Spravato |
| Avadel Cns Pharmaceuticals, LLC | $34.54 | 2025 | Lumryz |
| Takeda Pharmaceuticals U.S.A., INC. | $31.36 | 2024-2025 | Trintellix |
| Biogen, INC. | $29.74 | 2025 | Zurzuvae |
| Noven Therapeutics, LLC | $24.87 | 2024 | Xelstrym |
| Neos Therapeutics, Lp | $15.66 | 2025 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $14.26 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Frazier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.